Partners News Xenikos enrolls first patient in global pivotal phase 3 study evaluating T-Guard

30 June 2022

This week, Xenikos announced the first patient dosed in their Phase 3 study for T-Guard, a candidate for the treatment of severe acute graft-versus-host disease (aGVHD). 

Learn more in their press release.

Related news items

Successful matchmaking at Radboudumc Investment Day  

7 October 2022

On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.

read more

Radboudumc Investment Day 2022

26 September 2022

Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!

read more

Simmunext: where immunotherapy and chemistry meet

2 June 2022 The story behind Radboud university medical center’s, Radboud University’s and Oncode’s newest spinoff, Simmunext Biotherapeutics B.V. read more

T-Guard can reset immune system

1 December 2021 For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard. read more

BIOTRIP vision for biotech incubator

9 November 2021 BIOTRIP, the biotech incubator, presents its vision. read more

Radboudumc and Radboud University strengthen collaboration with Janssen

17 March 2019 On March 12, Radboudumc and Radboud University have signed a letter of intent for intensified collaboration with Janssen. read more